Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGb 761

Drug Profile

EGb 761

Alternative Names: GBE 761; Gingogink; Ginkgo biloba special extract - Dr Wilmar Schwabe Group/Ipsen; Tanakan; Tebonin; Tramisal

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr. Willmar Schwabe Pharmaceuticals
  • Developer Dr. Willmar Schwabe Pharmaceuticals; Ipsen
  • Class Antiplatelets; Herbal medicines; Phytotherapies
  • Mechanism of Action Antioxidants; Nitric oxide synthase type II inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Ear disorders; Eye-Disorders; Neurological disorders; Vascular disorders
  • Phase III Tinnitus
  • Phase II Vertigo
  • No development reported Friedreich's ataxia
  • Discontinued Pancreatic cancer

Most Recent Events

  • 31 May 2018 Dr Willmar Schwabe GmbH completes a phase II trial in Vertigo in Poland (PO, Tablet) (ISCRTN83227991)
  • 19 Dec 2017 Dr. William Schwabe Pharmaceuticals completes a phase II trial in Tinnitus in Poland (EudraCT2016-000315-32)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Tinnitus(Combination therapy) in Switzerland (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top